Answers are grounded in this paper and cite their sources.
Against the backdrop of a global aging population, the decline in skeletal muscle mass and function caused by sarcopenia has become a significant clinical issue. Existing evidence suggests that the structural disintegration of the neuromuscular junction (NMJ) may precede muscle fiber atrophy and is a key step in disease progression; however, its early driving factors remain unclear. This article proposes, from an interdisciplinary perspective combining immunology and neuromuscular physiology, that inflammation- and aging-related remodeling of the immune microenvironment may be a key mechanism underlying NMJ degeneration, particularly in older adults with a high inflammatory burden. Local immune cell activation and age-related reprogramming interact with the NMJ’s inherent vulnerability: presynaptic terminals are sensitive to oxidative stress, and the synaptic region lacks a blood-nerve barrier. Local immune cells can influence postsynaptic receptor expression via pro-inflammatory factors, disrupt the basal lamina through excessive synaptic pruning, and amplify oxidative stress due to decompensation of non-neuronal cholinergic anti-inflammatory pathways, thereby inducing autoimmune-like reactions. Terminal Schwann cells (tSCs), acting as local sentinels, convert synaptic stress into signals for immune cell recruitment. Furthermore, chemokines released from degenerating NMJs further recruit inflammatory cells, creating a vicious cycle in which metabolic dysfunction, immune activation, and tissue destruction mutually reinforce one another. Based on this, this paper proposes a triple pathological model involving immune instability, NMJ disintegration, and muscle fiber degeneration, and advocates expanding intervention targets from individual muscle fibers to the NMJ immune-synaptic microenvironment. Interventions focused on lifestyle, myeloid cell reprogramming, the complement system, and synaptic-targeted approaches—combined with measurable endpoints—may provide new translational pathways for the early prevention and treatment of sarcopenia.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: